Email Us
Call Us
AUSTIN, Texas – August 24, 2026 – Altogen Labs is a GLP-compliant global contract research organization providing comprehensive preclinical research services to pharmaceutical companies, biotechnology firms, and cancer research institutions worldwide.
Headquartered in Austin, Texas, and operating continuously since 2009, Altogen Labs supports the development of new therapeutics by offering cutting-edge laboratory capabilities in oncology, toxicology, gene expression, and pharmacology. With a focus on accelerating the discovery of novel anti-cancer treatments, the company has established an extensive portfolio of over 100 in-house validated xenograft models and advanced in vivo toxicology services for investigational new drug (IND) studies – an integration that allows efficacy and safety data to be generated in the same facility, by the same scientists, under the same quality system.
The company’s oncology research services include conventional cell line-derived xenografts (CDX), patient-derived xenografts (PDX), patient-derived cell cultures (PDC), and organoids (PDOrg), enabling accurate modeling of human cancer biology and therapeutic responses. These models are genetically and clinically characterized to improve translational relevance and predict drug efficacy with high confidence. Characterization matters because model selection is among the highest-leverage decisions in a preclinical program. A compound evaluated against a tumor that does not carry its target produces a null result that says nothing about the compound. Altogen Labs profiles its models by driver genetics – across receptor status, kinase pathway alterations, tumor suppressor function, and repair pathway competence – so that sponsors select on biology rather than availability. Every model enters the collection only after tumor growth curves have been established and reproduced across multiple independent studies, ensuring predictable kinetics and interpretable results.
Altogen Labs also offers advanced immuno-oncology platforms utilizing humanized and immunodeficient rodent models, including those engrafted with PBMCs, CD34+ hematopoietic stem cells, and iPSCs. These platforms facilitate the investigation of tumor-immune system interactions and immunotherapeutic strategies. The distinction is mechanistic rather than technical: checkpoint inhibitors, immune agonists, bispecific T cell engagers, and cell therapies depend on engagement with a functioning immune compartment, and for agents whose binding is human-specific, murine immunity cannot substitute. The company additionally maintains syngeneic and allograft murine models for programs requiring fully immunocompetent hosts, allowing sponsors to match the immunological context to the mechanism under investigation.
Efficacy and safety studies are critical components of preclinical drug development. Efficacy studies evaluate whether a compound produces its intended therapeutic effect under controlled conditions, optimize dosing strategies, and determine treatment duration and administration routes. Study designs accommodate single-agent evaluation and combination regimens against standard chemotherapy, targeted agents, or immunotherapy, with concurrent, sequential, and staggered scheduling. In parallel, safety studies assess the toxicological profile of investigational drugs, including acute, sub-chronic, and chronic toxicity, as well as their effects on major organ systems. Altogen Labs conducts in vivo LD50 determination in mice and rats, toxicokinetics, and OECD-guideline protocols spanning acute oral toxicity, repeated-dose oral toxicity, acute dermal toxicity and irritation, acute inhalation toxicity, chronic toxicity, and carcinogenicity — internationally harmonized methodology that produces data recognized across regulatory jurisdictions rather than requiring repetition for a second submission.
Running both workstreams under one roof eliminates the cross-laboratory variability that complicates exposure-margin calculation, and produces the efficacy-to-safety comparison that defines a therapeutic window. Both GLP and non-GLP formats are available, allowing exploratory work to proceed economically while pivotal studies receive full GLP execution. Altogen Labs offers both efficacy and safety services designed to meet regulatory requirements and support successful IND applications.
In addition to oncology, Altogen Labs conducts preclinical studies in fields such as inflammation, immunology, neurodegenerative disease, pain, infectious disease, and metabolic disorders. Core services include xenograft tumor growth delay (TGD) studies, in vivo toxicology, RNAi and gene expression analysis, biodistribution and imaging studies, stable cell line development, and tissue culture testing. Supporting capabilities span pharmacokinetic and pharmacodynamic analysis, CRISPR/Cas9 gene editing, microfluidics-based liposome and nanoparticle encapsulation, tissue-targeted in vivo delivery, custom ELISA and cell-based assay development, immunohistochemistry, histopathology, flow cytometry, GLP-compliant cell banking, and microorganism identification with 16S sequencing. These integrated services ensure a thorough evaluation of a compound’s pharmacological activity, safety, and therapeutic potential.
All work is conducted in the company’s GLP-compliant, IACUC-regulated Austin facility by experienced scientists, supported by dedicated technical and QA/QC teams. Altogen Labs maintained IACUC-regulated animal operations throughout its history. Sponsors receive detailed experimental procedures, animal health reports, and an all-inclusive final report containing methods, results, discussion, raw data, and complete statistical analysis. One hundred percent of intellectual property generated in the course of a study belongs to the client.
Work performed at Altogen Labs has supported peer-reviewed publications, international patent filings, IND applications, and the development programs of clinical-stage and publicly traded biopharmaceutical companies. By combining scientific expertise with cutting-edge technology, Altogen Labs serves as a trusted research partner dedicated to accelerating the translation of laboratory discoveries into clinical therapies.
About Altogen Labs
Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research services and biology CRO services to pharmaceutical companies, biotechnology firms, and academic institutions worldwide. The company maintains a large collection of in-house validated xenograft models – CDX, PDX, syngeneic, organoids, and NAMs – and extensive experience in efficacy xenograft studies and safety toxicology studies supporting IND applications and regulatory submissions.
Contact Information
Altogen Labs 11200 Menchaca Rd, Bldg 2, Suite 203 Austin, TX 78748 USA Tel: 512-433-6177 Email: info@altogenlabs.com Web: altogenlabs.com